Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients
暂无分享,去创建一个
K. Ishak | F. Mullick | L. Seeff | H. Zimmerman | J. Lewis | R. Ranard | A. Caruso | L. Jackson | A. Caruso | J. Lewis
[1] H. Zimmerman,et al. SERUM ENZYMES IN DISEASE: VII. SIGNIFICANCE OF ABNORMAL SERUM ENZYME LEVELS IN CARDIAC FAILURE , 1961, The American journal of the medical sciences.
[2] S. Richman,et al. Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes. , 1961, The American journal of medicine.
[3] H. Zimmerman,et al. Serum enzymes in disease. IX. Analysis of factors responsible for elevated values in infectious mononucleosis. , 1962, The American journal of medicine.
[4] C. Heusghem,et al. Long-term hepatic tolerance of amiodarone in the clinic. , 1969, European journal of pharmacology.
[5] A. Vos,et al. A peculiar cutaneous pigmentation from cordarone. , 1972, Dermatologica.
[6] K. Nagashima,et al. DRUG‐INDUCED GENERALIZED PHOSPHOLIPIDOSIS , 1972, Acta pathologica japonica.
[7] M. Jonckheer,et al. Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone. , 1973, Acta cardiologica.
[8] R. Lüllmann-Rauch,et al. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. , 1975, CRC critical reviews in toxicology.
[9] P. Nicod,et al. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones. , 1976, The Journal of clinical investigation.
[10] S. R. Mills,et al. Computed Tomography in the Diagnosis of Disorders of Excessive Iron Storage of the Liver , 1977, Journal of computer assisted tomography.
[11] H. Zimmerman,et al. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .
[12] K. Kenyon,et al. Amiodarone keratopathy: drug-induced lipid storage disease. , 1981, Archives of ophthalmology.
[13] E. Prystowsky,et al. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. , 1981, The New England journal of medicine.
[14] L. Horowitz,et al. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. , 1982, The American journal of cardiology.
[15] M. Josephson,et al. Amiodarone pulmonary toxicity. , 1982, Annals of internal medicine.
[16] E. Chew,et al. Amiodarone-induced cornea verticillata. , 1982, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[17] K. Bizière,et al. Amiodaron neuropathy: further arguments for human drug-induced neurolipidosis. , 1982, European neurology.
[18] J. Doppman,et al. Computed Tomography of the Liver and Kidneys in Glycogen Storage Disease , 1982, Journal of computer assisted tomography.
[19] V. Huckell,et al. Diffuse alveolar damage syndrome associated with amiodarone therapy. , 1983, Canadian Medical Association journal.
[20] W. Mckenna,et al. Side effects and possible contraindications of amiodarone use. , 1983, American heart journal.
[21] F. Morady,et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. , 1983, The American journal of cardiology.
[22] P. Kudenchuk,et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. , 1983, Journal of the American College of Cardiology.
[23] J. Alpert,et al. Clinical Pharmacokinetics and Efficacy of Amiodarone for Refractory Tachyarrhythmias , 1983, Circulation.
[24] R. Winkle,et al. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. , 1983, Circulation.
[25] J. Ruskin,et al. Adverse reactions during treatment with amiodarone hydrochloride. , 1983, British medical journal.
[26] P. Adams,et al. High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion. , 1983, Journal of clinical pathology.
[27] P. K. Lim,et al. Neuropathy and fatal hepatitis in a patient receiving amiodarone. , 1984, British medical journal.
[28] R. Miller,et al. Dermal lipofuscinosis associated with amiodarone therapy. Report of a case. , 1984, Archives of dermatology.
[29] K. Hostetler,et al. Chloroquine treatment does not cause phospholipid storage by depleting rat liver lysosomes of acid phospholipase A. , 1984, Biochimica et biophysica acta.
[30] S. Sherlock,et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. , 1984, Gut.
[31] L. Horowitz,et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. , 1984, Annals of internal medicine.
[32] P. Friedman,et al. Pneumonitis after amiodarone therapy. , 1984, Radiology.
[33] M. Shenasa,et al. Abnormal abdominal computerized tomography with amiodarone therapy and clinical significance. , 1984, American heart journal.
[34] F. Morady,et al. Frequent neurologic toxicity associated with amiodarone therapy , 1984, Neurology.
[35] P. Armstrong,et al. Amiodarone hepatotoxicity simulating alcoholic liver disease. , 1984, The New England journal of medicine.
[36] F E White,et al. Long-term amiodarone therapy: a cause of increased hepatic attenuation on CT. , 1984, The British journal of radiology.
[37] J. Joelson,et al. Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy. , 1984, Chest.
[38] E. Downar,et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. , 1984, Gastroenterology.
[39] T. Sarna,et al. Clinical and morphologic effects of amiodarone on the liver. , 1985, Gastroenterology.
[40] P. Yagupsky,et al. Fatal hepatic failure and encephalopathy associated with amiodarone therapy. , 1985, The Journal of pediatrics.
[41] H. Goldberg,et al. Increased hepatic density and phospholipidosis due to amiodarone. , 1985, AJR. American journal of roentgenology.
[42] R. Fruncillo,et al. Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in the rat , 1985, The Journal of pharmacy and pharmacology.
[43] D. Capron-Chivrac,et al. [Acute hepatopathy caused by amiodarone. Study of a case and review of the literature]. , 1985, Gastroenterologie clinique et biologique.
[44] B. Lown,et al. Side effects and complications of amiodarone therapy. , 1985, American heart journal.
[45] M. Nicholson,et al. Value of hepatic computerized tomographic scanning during amiodarone therapy. , 1985, The American journal of cardiology.
[46] K. Nademanee,et al. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. , 1986, The American journal of cardiology.
[47] E. Downar,et al. Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. , 1986, Thorax.
[48] J. Lupón-Rosés,et al. Probable early acute hepatitis with parenteral amiodarone , 1986, Clinical cardiology.
[49] K. Hostetler,et al. Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. , 1986, Biochimica et biophysica acta.
[50] W. M. Smith,et al. Long-term tolerance of amiodarone treatment for cardiac arrhythmias. , 1986, The American journal of cardiology.
[51] M. Josephson,et al. Amiodarone Hepatotoxicity: A Clinicopathologic Study of Five Patients , 1986 .
[52] J. Rumessen. Hepatotoxicity of amiodarone. , 2009, Acta medica Scandinavica.
[53] R. Crapo,et al. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias. , 1986, The Canadian journal of cardiology.
[54] D. Dhumeaux,et al. Chronic liver disease after low daily doses of amiodarone. Report of three cases. , 1986, Journal of hepatology.
[55] J. Porterfield,et al. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. , 1987, American journal of clinical pathology.
[56] J. Mason. Drug therapy: amiodarone , 1987 .
[57] L. Bertilsson,et al. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.
[58] M. Josephson,et al. Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. , 1987, The American journal of medicine.
[59] N. Shepherd,et al. Granular cells as a marker of early amiodarone hepatotoxicity: a pathological and analytical study. , 1987, Journal of clinical pathology.
[60] M. Pirovino,et al. Amiodarone‐induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model , 1988, Hepatology.
[61] Gilinsky Nh,et al. Fatal amiodarone hepatoxicity. , 1988 .
[62] K. Hostetler,et al. In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. , 1988, Biochimica et biophysica acta.
[63] S Kacew,et al. Amiodarone-induced phospholipidosis in rat alveolar macrophages. , 1988, The American review of respiratory disease.